SciBase Holding AB (SCIB.ST), a medical technology company, announced that its new study has enrolled its first patient to assess flare prediction in Atopic Dermatitis.
Atopic dermatitis, often referred to as eczema, is a long-lasting condition characterized by dry, itchy, and inflamed skin, resulting in recurrent outbreaks known as flares. While it can develop at any age, it is particularly prevalent in young children. (Source: Mayo Clinic)
The current treatment options address the symptoms only after the flare-ups, which significantly impacts patients' daily lives, noted the firm.
In accordance with the present feedback, the company has collaborated with Castle Biosciences and has developed a study titled DETECT-AD. The study will utilize SciBase's Electrical Impedance Spectroscopy (EIS) method to predict the onset of flares in patients with atopic dermatitis.
The company stated that this study aims to shift the focus toward proactive and personalized care, which is intended to enhance patients' quality of life and lessen the impact of unpredictable flare-ups.
SciBase is currently trading on the Stockholm Stock Exchange at SEK 50.20, up 2.03%.
For more such biotech stock news, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.